香港本土首家生物科技類公司今日敲鐘,中國抗體-B(3681.HK)上市股價每股7.6港元
格隆匯11月12日丨中國抗體-B(03681.HK)今日於港交所上市,公司發行1.82億股,每股定價7.6港元,每手300股,其中公開發售階段獲得12.87倍認購,一手中籤率100%。
公告顯示,公司由前香港中文大學教授、前香港生物科技院院長、港交所生物科技諮詢小組顧問樑瑞安博士於2001年在香港創立,是首家專門研究、發展、製造及商業化免疫性疾病療法的香港本土生物製藥公司,主要研製以單克隆抗體為基礎的生物藥。
基石投資者方面,包括雲南白藥集團股份有限公司以及深圳市高特佳投資集團有限公司參與基石認購。
在研產品管線上,中國抗體核心產品SM03有望成為全球首例針對類風濕關節炎的抗CD22單抗藥物,目前在中國針對類風濕性關節炎已進入臨牀III期試驗,預計今年年底完成招募工作,預計2021年上市。第三代BTK抑制劑SN1011目前在澳洲處於臨牀I期試驗,預計今年年底完成,並計劃在中國藥監局提交IND,啟動臨牀試驗。針對過敏性哮喘上,中國抗體的在研產品SM17為首款針對IL-17BR的標靶抗體,能夠對應多種適應症,目前準備提交IND,預計2021年第一季度進入臨牀I期試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.